Key result
An ALARA protocol for pediatric SVT ablation achieved a 95% acute success rate with no complications and a median dose area product of 343.2 uGym2, lower than prior EAM/fluoro data.
Why the study?
Does an ALARA radiation reduction protocol reduce radiation dosage in pediatric patients undergoing SVT ablation?
Observational (n=42)
No
Does an ALARA radiation reduction protocol reduce radiation dosage in pediatric patients undergoing SVT ablation?
An ALARA protocol using low frame rates and low fluoroscopy dose per frame significantly reduces radiation exposure during pediatric SVT ablations while maintaining high procedural success and safety without the need for electroanatomical mapping.
ALARA may reduce radiation in pediatric SVT ablation without safety loss; leaves open randomized confirmation before practice change.
BACKGROUND: Ablation for supraventricular tachycardia (SVT) relies upon fluoroscopy (fluoro), which exposes the patient and staff to ionizing radiation. The objective of this work was to present a new "ALARA--As Low As Reasonably Achievable" protocol with alterations to fluoroscopic x-ray parameters to reduce dose without an electroanatomical (EAM) approach. METHODS: All patients <21 years of age undergoing ablation of SVT at our institution from June 2011 to April 2012 were included. EAM was not utilized in any case. An ALARA protocol of low frame rates (2 or 3 fps), low fluoro dose/frame (10-18 nGy/frame), and other techniques aimed at reducing use of fluoroscopy were employed. Demographics, procedural, and radiation data were analyzed. RESULTS: Forty-two patients underwent ablation and were studied. Median age was 14.1 years (range 4.8-21.1 years), weight was 51 kg (range 18.2-75 kg), and body surface area was 1.51 m(2) (range 0.72- 1.94 m(2)). Seventeen (41%) had Wolff-Parkinson-White syndrome, 14 (33%) atrioventricular nodal reentrant tachycardia, and 11 (26%) concealed pathways. Median procedural time was 114 minutes (57-246 minutes). Median dose area product (DAP) for posterioanterior and lateral fluoroscopy was 343.2 uGym(2) (range 38.2-3,172 uGym(2)); the median air Kerma product (K) was 45.4 mGy (range 6.7-567.5 mGy). DAP and K are lower than prior data from EAM and fluoroscopy techniques. The acute success rate was 95%; no procedural complications. CONCLUSIONS: An ALARA protocol for ablation of SVT reduced radiation to below levels previously reported for combined EAM/fluoro approaches. Success rates were excellent with no complications and without the costs of EAM.
No takes yet. Share an insight, caveat, or question.
Gellis et al. (2013) conducted an observational in Supraventricular tachycardia (SVT) (n=42). ALARA radiation reduction protocol vs. Prior data from EAM and fluoroscopy techniques was evaluated on Radiation dose (DAP and air Kerma product) and acute success rate. An ALARA protocol for pediatric SVT ablation achieved a 95% acute success rate with no complications and a median dose area product of 343.2 uGym2, lower than prior EAM/fluoro data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: